Diverse Hematological Malignancies Including Hodgkin-Like Lymphomas Develop in Chimeric MHC Class II Transgenic Mice by Raffegerst, Silke H. et al.
Diverse Hematological Malignancies Including
Hodgkin-Like Lymphomas Develop in Chimeric MHC
Class II Transgenic Mice
Silke H. Raffegerst
1,2*, Gabriele Hoelzlwimmer
3¤a, Sandra Kunder
3¤b, Josef Mysliwietz
1, Leticia
Quintanilla-Martinez
3¤c, Dolores J. Schendel
1,2
1Institute of Molecular Immunology, Helmholtz Zentrum Mu ¨nchen, German Research Center for Environmental Health, Munich, Germany, 2Clinical Cooperation Group
Immune Monitoring, Helmholtz Zentrum Mu ¨nchen, German Research Center for Environmental Health, Munich, Germany, 3Institute of Pathology, Helmholtz Zentrum
Mu ¨nchen, German Research Center for Environmental Health, Neuherberg, Germany
Abstract
A chimeric HLA-DR4-H2-E (DR4) homozygous transgenic mouse line spontaneously develops diverse hematological
malignancies with high frequency (70%). The majority of malignancies were distributed equally between T and B cell
neoplasms and included lymphoblastic T cell lymphoma (LTCL), lymphoblastic B cell lymphoma (LBCL), diffuse large B cell
lymphoma (DLBCL), the histiocyte/T cell rich variant of DLBCL (DLBCL-HA/T cell rich DLBCL), splenic marginal zone
lymphoma (SMZL), follicular B cell lymphoma (FBL) and plasmacytoma (PCT). Most of these neoplasms were highly similar to
human diseases. Also, some non-lymphoid malignancies such as acute myeloid leukemia (AML) and histiocytic sarcoma
were found. Interestingly, composite lymphomas, including Hodgkin-like lymphomas, were also detected that had CD30
+
Hodgkin/Reed-Sternberg (H/RS)-like cells, representing a tumor type not previously described in mice. Analysis of
microdissected H/RS-like cells revealed their origin as germinal center B cells bearing somatic hypermutations and, in some
instances, crippled mutations, as described for human Hodgkin lymphoma (HL). Transgene integration in an oncogene was
excluded as an exclusive driving force of tumorigenesis and age-related lymphoma development suggests a multi-step
process. Thus, this DR4 line is a useful model to investigate common molecular mechanisms that may contribute to
important neoplastic diseases in man.
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Introduction
The similarities between genomes and genetic pathways
underlying tumor development in mice and humans make mouse
models ideal for the study of cancer pathogenesis. Numerous
inbred, virus-induced or genetically-engineered mouse models of
human malignancy have been developed in the past to gain insight
into mechanisms of tumorigenesis.
Several mouse models exist for hematopoietic malignancies
which correspond to distinct tumor entities, including B or T cell
lymphomas or myeloid leukemias [1,2]. A number of these models
rely on tumor transplantation, which poorly reflects the process
that occurs in human malignancy, particularly with respect to
multi-step events. This can be partially rectified with the use of
spontaneous tumor models that are created by introducing known
genes, such as chromosomal translocations which occur in human
tumors. As examples, B cell malignancies were induced by
translocation of the myc-locus [3], knock-in of the proto-oncogene
Bcl-6 [4] or knock-out of the p53 tumor suppressor gene [5].
Spontaneous T cell malignancies were generated by expression of
mutated Notch1 [6], in Emu-myc transgenic mice [7] or by
induction of Moloney mouse leukemia virus [8]. Furthermore,
leukemic malignancies were forced through integration of fusion-
genes that mimic chromosomal alterations, such as myc-IgH [9],
CALM/AF10 [10] or through introduction of murine leukemia
viruses (MuLV) [11]. These various models share the characteristic
that principally one distinct lineage-specific tumor-type is detected
in each mouse strain.
We discovered that an established MHC class II transgenic (tg)
mouse line, developed by Ito and coworkers as a model for
autoimmunity [12] developed spontaneous tumors starting around
eight months of age. Extensive cellular and molecular character-
ization revealed that widely diverse hematopoietic neoplasms occur
in these mice, which arise from different lineages and represent
different stages of lymphocyte development. Surprisingly, many of
these neoplasms had phenotypes that are characteristic of human
hematological diseases. Therefore, this mouse line provides a
unique tumor model that broadly extends the possibilities to study
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8539potential multistep-processes involved in tumorigenesis in vivo, with
high relevance to human hematological malignancy.
Results
Various Hematological Malignancies Develop in DR4-H2E
and F1 Mice
The previously published DR4-H2E transgenic mouse line
expresses a chimeric human-mouse MHC class II gene (HLA-
DR4/H2E
d). DR4-H2E mice express MHC class II chimeric
molecules, composed of the human DR4a and DR4b peptide
binding-domains, coupled to mouse MHC class II (H2Ea
d and
H2Eb
d) constant domains, respectively. One DR4-H2E transgenic
founder line was backcrossed to MHC class II-deficient mice
(C2d–C57BL/6 background) to eliminate expression of endoge-
nous mouse class II molecules and DR4-H2E homozygous mice
(hereafter DR4 mice) were established [12]. All offspring of DR4
parental mice expressed chimeric class II molecules on splenic B
cells but not T cells, as depicted using a monoclonal antibody
specific for human DRB1*0401 molecules (data not shown). These
results confirmed homozygosity of the DR4-H2E transgene in the
parental line. Cellular interactions were preserved with CD4
coreceptors on murine T cells by retaining the alpha-2 and beta-2
domains of mouse MHC class II in the chimeric protein.
Our new finding is that DR4 mice spontaneously develop
hematopoietic malignancies at high frequency (69.7%). To explore
the role of DR4 homozygosity versus murine H2 class II deficiency
on tumor occurrence, DR4 animals were crossed with wildtype
C57BL/6 mice, yielding DR4 heterozygous F1 mice which carry
one normal H2
b MHC haplotype and thereby are no longer
H2 class II deficient. Tumor development in F1 mice would
imply a dominant oncogenic effect associated with DR4-H2E
transgene heterozygosity and only a minor contribution of H2
class II deficiency to tumorigenesis. Indeed, DR4 heterozygous
F1 mice also developed different types of lymphoma with high
frequency, as described in more detail below. Tumor appearance
was assessed in 132 DR4 and 125 F1 mice, yielding frequencies
of 69.7% (92 of 132) and 52.8% (66 of 125), respectively
(Figure 1A).
Tumors were classified histologically according to the Bethesda
Proposal for lymphoid and non-lymphoid hematopoietic neo-
plasms in mice [1,2]. Expression of lineage-specific markers was
assessed by immunohistochemistry to support histopathology and
was confirmed in many cases by multi-parameter flow cytometry
of thymic or splenic single cell suspensions. The hematologic
neoplasms arising in DR4 and F1 mice were similar (Figure 1B).
Most malignancies were of lymphoid origin with 35.9% (33 of 92)
T cell tumors and 39.1% (36 of 92) B cell tumors in DR4 mice
(Table 1). Several cases of AML (4.3%) and two cases of histiocytic
sarcoma were also observed. Furthermore, 16.3% of animals had
composite tumors with mixtures of B cell and T cell tumors or B
cell tumors with AML (Figure S1). Some composite tumors
contained mononucleated Hodgkin-like or multinucleated RS-like
cells (see below). These lymphomas accounted for 10.9% of
malignancies and were generally a mixture of T cell/histiocytic
rich variant of DLBCL and LTCL. A similar occurrence of HL in
composite lymphomas appearing with LBCL [13], with the T cell
rich variant of DLBCL [14] or with MZL [15] has been described
previously in man.
Characterization of T Cell Neoplasms
All murine T cell neoplasms were diagnosed as lymphoblastic T
cell lymphomas (LTCL). These had a typical ‘‘starry sky’’ pattern
(Figure 2A) with massive infiltration of lymph nodes, spleen, lung,
kidneys and liver (Figure 2B). These neoplasms represented a
monotonous population of medium-sized cells, with scant
cytoplasm and blastic chromatin with one to two small nucleoli,
intermingled with abundant histiocytes with tingible bodies.
Immunohistochemical analysis revealed that neoplastic cells were
terminal deoxynucleotidyl transferase (Tdt)- and CD3-positive
(Figure 2C–D) but negative for the B cell marker, B220. LTCL
were either single-positive (SP) CD4
+ or CD8
+ T cells (Figure 2E)
or double-positive (DP) CD4
+CD8
+ T cells (Figure 2F), as shown
by flow cytometry. Single-positive LTCL represent a common
Figure 1. Survival plot and comparison of neoplasm distribution between DR4 and F1 mice. (A) Tumor-free survival of DR4 and F1 mice
within 24 months shown by the frequency of diseased mice in DR4 and F1-strains in relation to their age. Each symbol represents one individual
mouse. Disease appeared at 8.5 months of age in DR4 mice whereas in the heterozygous F1 generation tumors could be observed at 7 months.
Around 70% of DR4 mice and 53% of F1 mice developed lymphomas, 30% and 47% survived, respectively. Results were subjected to statistical
analysis using GraphPad Prism v5.0 software (GraphPad Software, San Diego California USA, www.graphpad.com). Survival curves were analyzed
using the Kaplan-Meier method and were compared with the log-rank test and by median survival. Kaplan-Meier survival curve shows significantly
decreased median survival of DR4 compared with F1 mice. Median survival of DR4 was 16.5 months versus 15 months for F1-mice (log-rank test,
p=0.0159). Data represent DR4, n=131; F1, n=125. (B) Distribution of different neoplasms in DR4 mice compared with F1 mice. Both mouse strains
developed lymphoid tumors (T and B cell neoplasms) with a similar frequency of around 75%.
doi:10.1371/journal.pone.0008539.g001
Model of Diverse Lymphomas
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whereas DP LTCL have recognized human counterparts.
Molecular analysis of T cell receptor (TCR) usage indicated a
monoclonal origin of all T cell tumors that were examined in DR4
and F1 mice (Table S1 and Table S2). To assess clonality, we used
an RT-PCR-based TCR Vb-repertoire analysis detecting 21 Vb-
families [17]. All detected amplicons were sequenced and
evaluated for standard characteristics of functionally rearranged
Vb–chains: in-frame rearrangements, lack of stop-codons, con-
served cysteine at position 104 and the conserved Phe-Gly-X-Gly-
motive (IMGT-Database). Where possible, molecular character-
ization of LTCL was supported by TCR surface phenotyping of
neoplastic cells using corresponding Vb-specific monoclonal
antibodies. The frequency of tumor cells in starting materials of
LTCL varied from 36–99%, perhaps reflecting the status of tumor
progression in the examined animals (data not shown). Despite
cellular heterogeneity, the TCR Vb-repertoires of all tumors were
restricted to a few prominent amplicons. Furthermore, in all cases
but one (i.e. Mouse ID-10), only a single amplicon sequence
displayed the characteristics of a functional Vb-chain. In several
tumors, a second amplicon revealed a ‘‘non-functional’’ rear-
ranged TCR sequence. The presence of some contaminating
normal T cells was evident in the background of electrophero-
grams, but these sequences were below a signal threshold that
allowed individual sequences to be defined, suggesting they were
composed of mixtures of different sequences (data not shown). As
examples, Figure 2E shows a monoclonal SP CD4
+ tumor
expressing a Vb8.2-receptor representing 98% of splenic CD4 T
cells. The surface phenotype confirmed the TCR sequence
designation of this tumor (Mouse ID-8, Table S1). In the second
case, two Vb-receptor sequences were found by RT-PCR (Mouse
ID-10, Table S1) and surface phenotyping of DP CD4
+CD8
+
tumor cells showed staining with corresponding Vb-specific
monoclonal antibodies (Figure 2F). Confocal microscopy corrob-
orated that both Vb-chains were colocalized on individual cells
(Figure 2G). While human T cells naturally expressing two Vb-
chains have been reported previously [18], this has not been seen
with normal mouse T cells but has been observed for T cells from
TCR transgenic animals that co-express endogenous TCR [19].
Based on combined molecular and cellular analyses, the results
Table 1. Distribution of neoplasms in transgenic DR4-mice.
Type of neoplasm Number Frequency (%)
Lymphoblastic T cell lymphoma 33 35.9
Precursor lymphoblastic T cell lymphoma (CD4
+CD8
+ LTCL) 10 10.9
CD4+ T cell lymphoma (CD4
+ LTCL) 15 16.3
CD8+ T cell lymphoma (CD8
+ LTCL) 2 2.2
LTCL with undefined phenotype (no samples for FACS) 6 6.5
B cell neoplasms 36 39.1
Lymphoblastic B cell lymphoma (LBCL) 4 4.3
Diffuse large B cell lymphoma (DLBCL) (incl. 1x case with H/RS-like cells) 6 6.5
Diffuse large B cell lymphoma, rich in histiocytes (DLBCL-HA)=T cell rich diffuse large B cell lymphoma
(incl. 3 cases with H/RS-like cells)
6 6.5
Splenic marginal zone lymphoma (SMZL) 12 13.0
Follicular B cell lymphoma (FBL) 5 5.4
Plasmacytoma (PCT) 2 2.2
B natural killer cell lymphoma (BNKL) 1 1.1
Composite neoplasms 15 16.3
LTCL+DLBCL-HA (incl. 5 cases with H/RS-like cells) 7 7.6
SMZL+DLBCL-HA (incl. 1 case with H/RS-like cells) 1 1.1
DLBCL+LTCL (incl. 1 case of histiocytic sarcoma) 2 2.2
LBCL+LTCL 1 1.1
DLBCL+acute myeloid leukemia (AML) 1 1.1
LBCL+AML 1 1.1
SMZL+AML 1 1.1
SMZL+histiocytic sarcoma 1 1.1
Non-lymphoid neoplasms 66 . 5
AML 4 4.3
Histiocytic sarcoma 2 2.2
Other malignancies 22 . 2
Epidermal tumor 2 2.2
Number of diseased mice in study 92 100
Disease-free mice 40
Total number of mice in study S132
doi:10.1371/journal.pone.0008539.t001
Model of Diverse Lymphomas
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8539Figure 2. Lymphoblastic T cell lymphoma (LTCL). (A–D). Histology and immunohistochemistry of LTCL (all bars equal 50 mm). (A) LTCL consists
of uniform cells with scant cytoplasm showing high mitotic and apoptotic rates and the typical starry sky pattern (hematoxylin & eosin, H&E). (B)
CD3+ infiltrates in the liver. (C). Tumor cells are positively stained for Tdt (terminal deoxynucleotidyl transferase) and (D) CD3. (E–F) Flow cytometry
analysis of T cell receptor Vb-repertoire on tumor-bearing spleen samples. (E) Monoclonal single positive (SP) CD4+ LTCL. Dot plots - top: gated on
CD3+B2202 cells: CD4 versus CD8, middle: gated on SP CD4+ T cells showing the Vb8.2+ tumor cell population and an irrelevant Vb-chain (Vb6);
bottom: gated on DP CD4/Vb8.2 as shown in histogram all other Vb-families were negative. (F) Monoclonal precursor LTCL gated on CD3+ B2202
cells: top: CD4 versus CD8, middle: monoclonal DP CD4+CD8+ tumor cells expressing two Vb-chains (Vb7&Vb10), bottom: gated on DP Vb7/Vb10
tumor cells, as shown in histogram all other Vb-families were not expressed. (G) Lymphocytes were stained as for FACS-analyses; top: Vb7-PE in red,
middle: Vb10-FITC in green, bottom: merged image showing co-localization of Vb7-PE and Vb10-FITC as dual T cell receptors on splenic tumor cells
with deconvolution microscopy. All bars equal 5 mm.
doi:10.1371/journal.pone.0008539.g002
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examined in DR4 and F1 mice (Table S1 and Table S2).
Characterization of B Cell Neoplasms
The B cell neoplasms were morphologically very heterogeneous
but all were positive for CD79a (Iga) and/or B220. B cell
lymphoblastic lymphomas (LBCL) (Figure 3A+B) were character-
ized by medium-sized cells with scant cytoplasm, blastic chromatic
and one prominent nucleolus. These tumors showed massive
infiltration of different organs, starry sky patterns and numerous
mitotic figures. Tumor cells were positive for CD79a (Figure 3B),
B220 and Tdt. Diffuse large B-cell lymphomas (DLBCL)
(Figure 3C+D) had medium to large centroblastic and immuno-
blastic cells with pale cytoplasm, round vesicular nuclei and
prominent nucleoli. Many DLBCL showed conspicuous infiltration
with reactive CD3-positive T cells. Half of the DLBCL belonged
to the morphological histiocyte-associated variant DLBCL-HA
(Figure 3E+F), which corresponds to T cell/histiocytic rich variant
of DLBCL in man [20]. Splenic marginal zone lymphomas (SMZL)
(Figure 3G+I) were composed of monomorphic, pale tumor cells
with regular nuclei and abundant cytoplasm. Early cases were
restricted to the marginal zone and advanced cases showed invasion
into the red pulp of the spleen or rarely into other organs. Their low
proliferative activitywas reflectedbya lownumberofmitoticfigures
(data not shown). SMZL were always CD79a positive (Figure 3H)
and often negative for B220 (Figure 3I). The similarity of SMZL to
its human counterpart is very high. The murine follicular B cell
lymphoma (FBL) was characterized by a mixture of centrocytes and
Figure 3. B cell neoplasms. (A–K) Histology (H&E) and immunohistochemistry (all bars equal 50 mm). (A) Lymphoblastic B cell lymphoma (LBCL)
shows blastic nuclei with prominent nucleoli and numerous mitotic figures. (B) Staining for CD79a+. (C) Diffuse large B cell lymphoma (DLBCL)
consists of immunoblastic and centroblastic cells and is (D) CD79a+. (E) The histiocyte-associated variant (DLBCL-HA) shows participation of many
histiocytes and granulocytes. (F) B220+ DLBCL-HA. (G–I) The splenic marginal zone lymphoma (SMZL) is usually (H) CD79a+ but (I) B2202. (J) H&E of
follicular B cell lymphoma. (K–L) Well-differentiated plasmacytomas display (L) CD79+ plasma cells. (M–O) The cellular phenotype of the B natural
killer cell lymphoma (BNKL) is confirmed by (N) positively stained CD79a B cells and (O) DP B220/NK1.1 cells in FACS.
doi:10.1371/journal.pone.0008539.g003
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positive and negative for Bcl2 (data not shown). Although
morphologically similar to human lymphomas, the pathogenesis
of murine FBL seems to be different [21]. Well-differentiated
plasmacytomas (PCT) (Figure 3K+L) consisted of plasma cells in
different stages of maturation, which were positive for CD138 and
CD79a. One case of B natural killer cell lymphoma (BNKL) was
also found (Figure 3M–O). It consisted of large pale cytoplasm-rich
cells, often with indented nuclei and prominent nucleoli. Tumor
cells appeared as mature large B cells with surface expression of
CD79a (Figure 3N) and NK1.1 in FACS (Figure 3O). This tumor
lacks any known human counterpart.
FACS analysis confirmed a mature (B220
+IgM
+IgD
+)p h e n o t y p eo f
most B cell tumors, except LBCL. A few lymphomas had phenotypes
of small pre-Bcells(Mouse-ID 96,124;B220
+Ig
2CD117
2),pro B-cells
(Mouse-ID 109; B220
+Ig
2CD117
+) or immature B cells (Mouse-ID
48,111,129; B220
+IgM
+IgD
2)( T a b l eS 3a n d / o rT a b l eS 7 ) .T o
determine clonality, RT-PCR analysis was made with immuno-
globulin heavy chain (IgH)-specific primers for variable (V) and
joining (J)-regions. Clonality was identified by sequence homoge-
neity of the amplified IgH fragments. Since whole spleen samples
were used, a low background of contaminating sequences from
normal B cells was observed but these mixed signals were below the
threshold allowing individual sequence determination (data not
shown). Sequences were considered to be monoclonal and
functional if they were in-frame, had no stop-codons, a conserved
cysteine at position 104 (IMGT-Database) and a Trp-Gly-X-Gly-
motive similar to TCR analysis. Results indicated monoclonality in
80.6% of DR4 tumors and 78.6% of F1 tumors. In the remaining
samples,the VDJ-junctions werenot discernableastheyconsistedof
multiple sequences, indicating that these tumors were likely to be
oligoclonal. Further analysis of sequence data in comparison to
reported germline sequences [22] was performed to search for
mutations (silent or replacement mutations) in the framework
regions FR1-FR3 and the complementarity determining regions
CDR1–CDR3. The presence of mutations in FR1–FR3 and
CDR1–CDR2, in addition to mutations in the CDR3-regions of
VDJ-junctions, would indicate that tumor cells originated from
mature, activated B cells of germinal centers with ongoing somatic
hypermutations (SHM). Thirty percent of the examined DR4 B cell
tumors (9 of 30) but only 14% of F1 tumors (2 of 14) showed
mutations in the CDR3-regions of amplified IgH-rearrangements
(Table S3 and Table S4) (data for mutations in FR1-3 and CDR1–2
not shown).
CD30
+ Hodgkin/Reed Sternberg-Like Cells of B Cell Origin
Unusual cells were found in the majority of composite
lymphomas that were morphologically similar to human multinu-
cleated Reed Sternberg cells or mononucleated Hodgkin cells
(Figure 4A–H). These were designated as H/RS-like cells. A
polymorphic infiltrate of B and T cells as well as histiocytes and
plasma cells was detected surrounding the H/RS-like cells. Human
H/RS cells are known to express CD30 molecules. Concordantly,
murine H/RS-like cells in lymph node (Figure 4I–L) and spleen
(Figure 4M–P) were also CD30 positive. We therefore aimed to
determine whether these murine H/RS-like cells were of B cell
origin and if characteristic mutations could be found in their IgH
sequences. Such findings would further support their similarity to
human HL. The B cell origin of murine H/RS-like cells from five
mice was assessed using RT-PCR analysis of laser-assisted
microdissected pools of 8–10 cells for each splenic tumor. Pooling
of the cells was required to obtain adequate RNA from cells isolated
from cryopreserved H&E sections that were identified without
staining of specific markers but rather through morphologic
distinction of H/RS-like cells. Sequence analysis was performed
as described for B cell tumors above. Contaminating material from
neighbouring normal B cells, if present, was below the threshold of
detection in electropherograms.
Presence of IgH rearrangements showed that four tumors were
indeed derived from B cells. Furthermore, amplicon sequence
analysis and comparison with germline sequences (IMGT-
Database) demonstrated the presence of mutations in the FR1–
FR3 and CDR1–CDR3 regions of the specific amplicons,
reflecting the occurrence of somatic hypermutation that occurs
in germinal center (GC) B cells (Figure 4Q and data not shown).
Interestingly, in addition to mutations in FR1–FR3 and CDR1–2
regions, two sequences displayed deleterious ‘‘crippling’’ mutations
in their CDR3 regions, as has been reported for some human H/
RS-cells [23,24]. Based on IgH sequence comparisons of
nucleotides inserted within the VD and DJ junctions, a clonal
relationship was excluded between H/RS-like cells and tumor cells
of DLBCL-HA or SMZL in the same mouse (Table S5 and Table
S6).
Individual H/RS-like cells were positive or negative for B220
and were often surrounded by CD3
+ reactive T cell rosettes
(Figure 4R–T). Surface phenotypes of H/RS-like cells in
composite tumors were unclear due to low frequencies (2–5%) of
accompanying non-H/RS-like tumor cells (Table S7; File S1).
Loss of expression of B cell markers, such as B220 on H/RS-like
cells, was previously described for human H/RS cells [25]. In
total, the characterization of these unusual cells strongly suggests
that similar pathogenetic mechanisms may impact on the
phenotype of H/RS cells in humans and mice.
Impact of Transgene Integration
To determine whether transgene chromosomal integration
disturbed a known murine locus with oncogenic or suppressor
gene function, we sought to localize the exact insertion site. The
chimeric class II genes were created by replacing exon 2 of the
mouse gene with exon 2 of the corresponding human DR4 gene.
The two chimeric constructs (Figure 5A), also comprising the
locus control regions (LCR) of the mouse class II locus, were co-
microinjected into C57BL/6 blastocysts. Therefore, the chimeric
class II gene was expressed under the control of the natural
murine class II promoter [12]. To determine the chromosomal
integration site, we first performed fluorescence in-situ hybrid-
ization (FISH) using transgene-specific (DR4-exon2a and DR4-
exon2b) probes on splenocytes in metaphase. As indicated in
Figure 5B, the avidin-Cy3.5-labeled probe (DR4-exon2a) showed
a strong signal on both copies of chromosome 16 (comparable
data for DR4-exon2b not shown). The position of transgene
integration was estimated on chromosome 16 to be near
cytogenetic bands B3 to C2. The FISH analysis also revealed
that integration of both the DR4-chimeric alpha and beta
transgenes occurred together at a single location in the mouse
genome. To further pinpoint the exact localization of this
integration site, a genome walking analysis was performed using
transgene specific primers combined with adaptor primers
to ‘‘walk’’ from within the chimeric transgene to the murine
chromosomal boundary region, yielding a fusion-sequence.
This sequence contained DR4 transgene sequence at the
59-end and a murine chromosome 16 sequence at the 39-end
(Figure 5C). The exact integration site was located by BLAST
search of chromosome 16, at position +41138813 (Ensembl,
www.ensembl.org), corresponding to cytogenetic band B4
(Figure 5D). To date no known genes have been annotated in
the vicinity of this chromosomal region based on alignment with
Ensembl-Database.
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The development of diverse hematological malignancies in this
DR4 transgenic mouse line represents a unique phenotype that
has not been seen to date in other mouse tumor models. These
animals spontaneously develop a variety of lymphoid malignancies
in both the T and B cell lineages. Furthermore, the neoplasms
represent different developmental stages of T cells (DP and SP T
cells) and B cells (pre, pro, immature, mature, plasma cells). While
the majority of malignancies were derived from the lymphoid
lineage, the development of several cases of AML point towards
the possibility that lymphoid, or even earlier precursor cells with
lymphoid characteristics, occasionally transformed into myeloid
tumors, as recently proposed by others [10]. Malignant transfor-
mation was strongly restricted to the hematopoietic lineage since
only one case of carcinoma was observed in the more than 250
mice that underwent multi-organ histological examination. This
probably reflects a high propensity for rapidly dividing hemato-
poietic cells to undergo malignant transformation.
The expression of only one transgenic chromosome 16 in
heterozygous F1 mice was sufficient to allow development of
similarly diverse neoplasms. Since only 70% of DR4 mice and
53% of F1 mice developed tumors, DR4-H2E transgene
expression/integration alone was not sufficient for tumorigenesis.
The observation that malignancy first appeared around eight
months of age is consistent with a time-dependent, multi-step
process of transformation in these mice. The primary hit may
impact an early cell, perhaps a stem or early progenitor/precursor
cell, since some myeloid malignancies were observed but the final
events in tumorigenesis were only manifest at later stages of
cellular development. A single transformation event, occurring in
an early stem/precursor cell, seemed unlikely since this should
Figure 4. H/RS-like cells in composite lymphomas. (A-P+R-T) Histology and immunohistochemistry of Hodgkin-like lymphoma samples in
composite compartments, surrounded by activated B and T cells as well as histiocytes. (A–H). H&E staining of (A–D) lymph node and (E–H) spleen
sections containing Hodgkin/Reed-Sternberg (H/RS)-like cells (in white boxes). Magnification of characteristic (D+H) giant mononucleated Hodgkin-
like and (B+F) multinucleated RS-like cells. (K+L&O +P) CD30+ Hodgkin-like and (I+J&M +N) RS-like cells in (I–L) lymph node and (M–P) spleen
sections. (Q) CDR3-region of IgH-transcripts of microdissected H/RS-like cells from five different mice. (R–T) Immunohistochemistry of either B220
positive or negative (R) Hodgkin-like and (S) RS-like cells surrounded by (T) rosettes of CD3+ T cells. All bars equal 50 mm.
doi:10.1371/journal.pone.0008539.g004
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8539Figure 5. DR4-H2E constructs (DR4-a & DR4-b) and their genomic location after integration. (A) Schematic organization of the DR4-H2E
constructs according to Ito et al. [12]. The endogenous exons 2 of DR4-H2Ea and DR4-H2Eb of the H2d-haplotype were replaced by the human exons
2 of HLA-DRA*0101 and HLA-DRB*0401, respectively in the described restriction enzyme sites of an SK+ vector. (B+C) Mapping of the DR4 transgene
integration site. (B) left: Chromosomes from splenic metaphase; red circles mark the hybridization signals of a DR4-H2Ea-specific probe labeled with
avidin-Cy3.5. Exemplary illustration of DR4-H2Ea in the genomic region between the cytogenetic banding B3 and C2, right: Diploid set of
chromosomes arranged in a karyogramm. Both copies of chromosomes 16 show a hybridization signal (red circle) at the same genomic location.
(C+D) Exact localization of transgene integration in Chromosome 16. (C) Fusion sequence of transgene integration. The 59 end starts with the
transgenic sequence of a DR4-a-construct marked in the middle is the integration site followed by the endogenous sequence of the DR4 mouse
strain. Sequence was analyzed by using the NCBI-BLAST-software (http://www.ncbi.nlm.nih.gov/blast/) and determined at position +41138813
(Ensemble, www.ensemble.org). (D) Schematic diagram of Chromosome 16. The integration was localized to cytogenetic band B4 by genome
walking analysis.
doi:10.1371/journal.pone.0008539.g005
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were monoclonal with respect to TCR or IgH rearrangements.
Nevertheless, the strong propensity for B and T cell lymphomas
may be related to events occurring during Ig or TCR receptor
rearrangement that contributed to a postulated accumulation of
genetic hits needed for ultimate transformation. When tumors
were first apparent they were very aggressive and caused fulminant
and wide-spread disease, arguing against an early development
of tumors that remained quiescent and unseen during the first
months of life.
Among the diverse malignancies, the appearance of H-like
and R/S-like cells in the compartment of T cell/histiocytic-rich
DLBCL is of particular interest. Various investigators have
attempted to establish murine models of HL by transplanting
human HL cell lines or freshly isolated HL biopsies into
immunodeficient SCID mice [26,27,28]. These models are limited
by their xenogeneic nature, whereas the DR4 mice described here
provide cases of spontaneous disease with morphological and
phenotypic similarities to human T cell/histiocyte rich DLBCL
and HL with characteristic H/RS-like cells. Single cell analysis of
IgH-rearrangements in the H/RS-like cells revealed a B cell origin
in four of five examined cases. Furthermore, ‘‘crippled’’ mutations
in the hypervariable CDR3-regions suggested a pre-apoptotic
germinal center B cell origin in at least two cases, as shown for
some human H/RS cells [23,24]. In most human composite
lymphomas, a shared precursor for the HL and accompanying B
cell tumor was demonstrated by presence of common Ig sequences
and shared mutations [14,15]. In contrast, sequence comparisons
of the microdissected HL-like cells and the accompanying
DLBCL-HA or SMZL in DR4 mice showed clonally unrelated
VH,D H and JH-families. Likewise, the group of Caleo described
a composite human HL and mantle cell lymphoma as two
clonally unrelated tumors [29]. Furthermore, comparison of IgH
sequences with germline configurations revealed accumulation of
mutations in framework (FR1–FR3) and complementarity-regions
(CDR1–CDR3) of murine H/RS-like cells that were not detected
in accompanying DLBCL-HA or SMZL (data not shown),
revealing their origin from two distinct B cells. Nevertheless, the
appearance of additional mutations outside the CDR3-region
supports the conclusion that murine H/RS-like cells were derived
from GC B cells and the crippled mutations seen in two cases were
the result of ongoing somatic mutations rather than being due to
aberrant VDJ recombination.
The cellular and molecular analyses of the DR4 mice provide
substantial insight into the basis of tumor development. The
genomic DR4-H2E transgenes used for creation of DR4 mice
contained the murine class II promoter and locus control regions
(LCR), enabling natural expression of the chimeric proteins in the
appropriate cells and at the appropriate stages of development, as
expected for a normal H2 class II molecule [12]. Thereby, the
DR4-H2E transgene was not aberrantly expressed in time or place
in a manner that could contribute to tumor development.
It cannot be ascertained whether the chimeric class II protein
playsadirectroleinlymphomadevelopmentsinceonlyonefounder
line was retained by the original investigators and is available for
study today. To the best of our knowledge this type of lymphoma
development is unique to these DR4 mice since a literature search
did not reveal a similar phenotype in other MHC class II tg mice
[30,31]. However, long periods of observation may be needed to
detect tumors. If the DR4-H2E chimeric protein is directly
involved,itsexpressionaloneisnotsufficientfortumordevelopment
because only 70% of homozygous DR4 mice developed tumors, as
ascertained by monitoring of all DR4 mice throughout their entire
natural lifespan. It remains to be determined whether the chimeric
class II protein impinges on particular cellular interactions or
functions that could contribute to malignant transformation. It
should be noted that chimeric protein expression in tumor cells was
not essential, since the T cell tumors were all class II negative (data
not shown). H2 class II deficiency appeared not to be essential for
tumorigenesis since heterogenous F1 mice were also affected,
despite carrying one normal H2 haplotype. Since the frequency of
tumors was lower in F1 compared to DR4 mice, further studies are
required to determine if there is some subtle impact of H2 class II
deficiency on tumor development.
Atfirst,itseemedmostplausiblethattransgeneinsertionimpacted
on one or several murine loci, causing oncogenic effects. The finding
that integration of both constructs occurred at a single site ruled out
multiple hits due to multiple transgene insertion sites. Furthermore,
identification of the exact transgene integration site failed to reveal
disruption of a known suppressor gene or activation of a potential
oncogene since no annotated gene is located within 1 MB in both
directions of the insertion site. However, itis possiblethat long-range
effects on other loci, aberrant recombination events, or abnormal
chromosomal pairing and segregation caused by transgene integra-
tion could contribute to tumorigenesis. It is also possible that impacts
on non-coding sequences localized near the integration site could
play a role in tumor development. The age-related appearance of
tumors suggests a multi-step process. Future broad scale approaches,
therefore, will be needed to further pinpoint the complex mecha-
nisms contributing to lymphoma development.
In summary, this DR4 line is a unique lymphoma ‘‘generator’’
that yields diverse hematological malignancies. The majority of
lymphomas, including the DP LTCL, SMZL and DLBCL-HA
described in these mice, represent significant diseases in man,
whereas most other naturally occurring hematological tumors in
mice do not share major characteristics with human tumors [32].
The appearance of several cases of AML opens the door to better
elucidate the origin of these leukemias in relation to lymphoid
malignancies. Furthermore, the identification of neoplasms with
CD30
+ H/RS-like cells with a probable origin from GC B cells
may contribute to development of a long-sought mouse model for
human HL. Current xenogeneic models of HL are hampered by
low engraftment efficiency and the need for immune suppression.
In addition, these transplanted cells lack the characteristic
morphological phenotype of human HL. Therefore, a number
of features of the DR4 line make it a useful model to investigate
common molecular mechanisms that may contribute to important
neoplastic diseases in man. Based on the high frequency of
spontaneous tumor development, this DR4 line can also be used to
assess targeted therapies with potential for wide application in
different hematopoietic malignancies.
Material and Methods
Mice
DR4 tg mice have a C57BL/6 background [12] and were a
kind gift of Z. Nagy (Munich, Germany). Mice were bred and
propagated under SPF conditions. Mouse studies were conducted
according to German law by approved experimental protocols.
C57BL/6 mice (Taconic) were crossed with DR4 to generate F1
mice. At first sign of disease, animals were euthanized and
dissected organs prepared for histopathology, immunohistochem-
istry (formalin-fixed/paraffin-embedded or cryopreserved) and
flow cytometry (single cell suspensions).
Classification
The classification of lymphoid and non-lymphoid tumors was
based on the Bethesda Proposals [1,2] and was supported by
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supplementary data.
Histopathology/Immunohistochemistry (IHC)
Formalin-fixed lymph nodes, spleen and other organs were
embedded in paraffin, cut in 2–3 mm sections and stained with
H&E. Automated immunohistochemical staining (Ventana Med-
ical Systems) was performed as published [21] using the following
primary antibodies: CD45R/B220 (BD), CD3, CD79a, Tdt
(Dako), CD30 (Chemicon), CD49b (eBioscience), MPO (NeoMar-
kers). The L243 (HLA-DR) antibody was kindly provided by J.P.
Johnson (Ludwig-Maximilians-Universita ¨t, Munich, Germany).
Biotinylated goat anti-mouse (Dako) or goat anti-rabbit (Vector)
IgG antibodies were used as secondary reagents, linked to a
streptavidin-HRP-complex (Jackson Immunoresearch Laborato-
ries) and visualized with diaminobenzidine (Sigma-Aldrich).
Laser-Assisted Microdissection of Single Cells
Cryosections (12 mm) were transferred onto PEN-PALM
membrane slides (P.A.L.M.) and stained with H&E. Microdissec-
tion was performed in areas containing one H/RS cell. Up to
8–10 H/RS-like cells per sample were transferred into PALM
Adhesive Caps (P.A.L.M.) using the P.A.L.M MicroBeam
instrument. The mRNA was isolated with the BioNobile Quick
Pick mRNA-Isolation Kit (BioNobile) according to the manufac-
turer’s protocol and further processed with the message Booster
cDNA Synthesis Kit for qPCR (Epicentre).
RNA
RNA isolation of single cell suspensions or 20 mm thick tissue-
cryosections was performed using the RNeasy-Kit (QIAGEN)
following the manufacturer’s protocol. Total RNA (1 mg) was
reverse transcribed utilizing the AMV-First Strand cDNA-Synthesis
Kit (Roche).
Clonality Analysis of B Cells
Amplification of IgH rearrangements was performed by RT-
PCR on a LightCycler (LC) instrument (Roche) using the LC
FastStart DNA Master
Plus SYBR Green I–Kit. Degenerated IgH
forward 59-AGGTC/GA/CAA/GCTGCAGC/GAGTCATGG-
39 and IgH reverse 59TGAGGAGACGGTGACCGTGGT-
CCCTTGGCCCC-39 were kindly provided by R. Mocikat
(Helmholtz Zentrum Mu ¨nchen, Germany). The forward primer
annealed to the VH-region, the reverse primer to the JH-region
and yielded products of ,330 bp that included the VDJ-junction.
LC-PCR conditions used initial denaturation at 95uC for 10 min
followed by 35 cycles at 95uC for 0 sec, annealing at 65uC for
25 sec and elongation at 72uC for 25 sec. Specific fragments were
extracted with NucleoSpin Extract II-Kit (Macherey&Nagel) and
sequenced (Sequiserve) afterwards. Obtained sequences were
compared with germline configurations using IMGT/V-Quest
software on the IMGT website (http://imgt.cines.fr/IMGT_
vquest/share/textes/) [22,33].
Clonality Analysis of T Cells
TCR-Vb-repertoire analysis was performed by RT-PCR on a
Speed-Cycler instrument (Analytik-Jena) using a 59 forward primer
panel (21 Vb-family primers) described previously [17]. The reverse
TCR-Jb primer containing a GC-clamp 59-CGCCCGCCGC-
GCCCCGCGCCCGTCCCGCCGCCCCCGCCGGCTTGGG-
TGGAGTCACATTTCTC-39 was kindly provided by R. Mocikat.
In each PCR, 22 single reaction mixes were set up in a special
36-well-plate (Analytik-Jena). The volume of each single mix was
20 mL and contained all components except the primer (each
2.5 pmol) with 0.9 mL cDNA, 2 mL 10x buffer, 0.2 mM dNTPs,
0.5 mM MgCl2, 1 unit Taq polymerase and H2O. PCR conditions
used initial denaturation at 94uC 2 min, followed by 40 cycles of
denaturation at 94uC for 15 sec, annealing at 60uC for 25 sec,
elongation at 72uC for 30 sec and a final elongation of 72uCf o r
5 min. Editable sequences were compared with germline configu-
rations using IMGT/V-Quest software.
Flow Cytometry Analysis of TCR-Vb-Repertoires
TCR-Vb surface expression was analyzed using a mouse Vb
TCR Screening Panel Antibody Kit including 15 monoclonal
FITC-labeled antibodies (BD) as well as PE-labeled antibodies for
Vb8.1/8.2 and Vb7, CD3-PacBlue, CD4-AlexaFl700, CD8-APC-
Cy7, B220-PerCp-Cy5.5 (eBioscience). Staining was performed in
the presence of Fc-receptor blocking antibody (clone 2.4G8 kind
gift of E. Kremmer, Helmholtz Zentrum Mu ¨nchen). All cells were
processed on a LSRII Flow Cytometer (BD) and analyzed with
FlowJo8.7.1 software. Dead cells were excluded using propidium
iodide labeling and duplets by gating on single cells.
Confocal Microscopy
Cells were prepared as described for flow cytometry. Images
were acquired on a Personal Deltavision Microscope (Applied
Precision LLC). Image deconvolution was performed with a
constrained iterative algorithm as described [34] and analyzed
with SoftWoRx Suite software.
FISH Analysis
FISH analysis was performed on chromosome metaphase
spreads as described elsewhere [35,36]. Probes for FISH analysis
were specific for the human exon-2 sequence and were amplified
with hEx2a forward 59-GGGAAGCAGGGGGACTATGAC-39
andreverse primers59-CATTGGTGATCGGAGTATAGTTG-39
labeled with a Biochem-link kit from Roche followed by hybrid-
ization to chromosomal metaphase spreads of DR4 splenocytes.
The transgenic chromosome(s) positive for DR4-H2Ea were
tentatively identified by size and DAPI banding. Images were
recorded with a motorized Zeiss Axioplan Imaging II microscope
(Zeiss, Go ¨ttingen, Germany) and the Isis/V3.4.0-Software (Meta-
systems, Altlussheim, Germany).
Genome Walking
Genome walking analysis was performed with the Genome-
Walker Universal kit (BD Biosciences Clontech) according to the
user’s manual. Gene-specific primer (GSP) and adaptor primer
(AP) for the DR4-H2Ea-construct were used as follows aGSP1 59-
GGAGACCTCATCTTCTTCAGTTTCCAG-39, and aAP1 59-
GTAATACGACTCACTCACTATAGGGCACTATAGGGCA-
CGCGTGGT-39 for primary PCR and aGSP2 59-GTTTT-
TGTGCCTGAGCCAGTTCTTGGT-39, and aAP2 59-ACTA-
TAGGGCACGCGTGGT-39 for secondary PCR.
Accession Numbers
Sequence data of lymphoidreceptorswiththefollowingaccession
numbers FM179543–FM179580, FM179582–FM179603 and
FM179714–FM179741 can be accessed from EMBL Nucleotide
Sequence Database.
Supporting Information
Figure S1 Histological and immunohistological staining of
composite and non-lymphoid tumors. (A–H) Composite tumors
consisted of different types of lymphoid tumors (A–E) or a B cell
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thymus and lymph nodes (left side) is accompanied by a DLBCL in
the spleen (right side). (C) The LTCL is CD3
+ and (D) the DLBCL
is positive for CD79a. (E) Both composite tumors in the spleen are
of B-cellular origin: The DLBCL-HA on the left side can be
distinguished from the splenic marginal zone lymphoma (SMZL)
on the right side. (F–H) A composite tumor in the spleen, which
consists of (G) a B220-positive diffuse large B cell lymphoma
(DLBCL), and (H) an MPO-positive acute myeloid leukemia
(AML). (I–L) The well-differentiated acute myeloid leukemia
(AML) with maturation consists of myeloblasts (less than 90%) and
mature granulocytes with typical doughnut-like shape. (I) H&E
stained section, (J) Immunohistochemically, it is characterized by
myeloperoxidase (MPO) positivity of the mature granulocytes, (K)
B220- and (L) CD3- cells. (M) Histiocytic sarcoma in lymph node
section. All bars equal 50 mm.
Found at: doi:10.1371/journal.pone.0008539.s001 (1.41 MB TIF)
Table S1 T cell neoplasms in DR4 mice. Phenotypes of T cell
tumors and their monoclonal TCRVbeta chain sequences
(CDR3-region).
Found at: doi:10.1371/journal.pone.0008539.s002 (0.37 MB TIF)
Table S2 T cell neoplasms in F1 mice. Phenotypes of T cell
tumors and their monoclonal TCRVbeta chain sequences
(CDR3-region).
Found at: doi:10.1371/journal.pone.0008539.s003 (0.27 MB TIF)
Table S3 B cell neoplasms in DR4 mice. Phenotypes of B
cell tumors and their rearranged IgH-V family sequences
(CDR3-region).
Found at: doi:10.1371/journal.pone.0008539.s004 (0.38 MB TIF)
Table S4 B cell neoplasms in F1 mice (no FACS data).
Rearranged IgH-V family sequences (CDR3-region).
Found at: doi:10.1371/journal.pone.0008539.s005 (0.14 MB TIF)
Table S5 HL-like tumors in DR4 mice (microdissected pooled
single cells). Rearranged IgH-V family sequences (CDR3-region).
Found at: doi:10.1371/journal.pone.0008539.s006 (0.11 MB TIF)
Table S6 Composite tumors in DR4 mice (whole spleen
samples). Rearranged IgH–V family sequences (CDR3-region).
Found at: doi:10.1371/journal.pone.0008539.s007 (0.13 MB TIF)
Table S7 Immunhistology and flow cytometry of B cell
lymphomas.
Found at: doi:10.1371/journal.pone.0008539.s008 (0.36 MB TIF)
File S1 Flow cytometric classification of tumors Cell staining was
performed in the presence of Fc-receptor blocking antibody (clone
2.4G8, kind gift of E. Kremmer, Helmholtz Zentrum Mu ¨nchen)
using the following antibodies: FITC-labeled anti-CD62L, -TCRba,
-CD4, -IgD, -2.4G2, PE-labeled anti-TCRdg, -CD117 (ckit),
-CD11c, -CD70, -CD122, -CD86, APC-labeled anti-CD44, -IgM,
-CD49b, L243 (HLA-DR), APC-Cy7-labeled anti-CD19, anti-GR1,
-CD8, PE-Cy7-labeled anti-CD25, anti-CD11b CD4-Ax700,
B220-PerCpCy5.5, CD3-Pacific Blue. Flow cytometry analysis was
performed on a LSRII Flow Cytometer (BD) and analyzed with
FlowJo8.7.1-software. Dead cells were excluded using propidium
iodide labeling and duplets by gating on single cells (FSC-H to
FSC-A channel).
Found at: doi:10.1371/journal.pone.0008539.s009 (0.03 MB
DOC)
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